Methods and compositions for regulating cell cycle progression

Patent metadata

Field	Value
Publication number	US-9200275-B2
Application number	US-30496807-A
Country	US
Kind code	B2
Filing date	Jun 14, 2007
Priority date	Jun 14, 2006
Publication date	Dec 1, 2015
Grant date	Dec 1, 2015

Abstract

In one aspect, a method is provided of inhibiting proliferation of a mammalian cell comprising introducing into said cell an effective amount of at least one at least one small interfering RNA agent (iRNA), wherein said iRNA comprises a nucleotide sequence of at least 15 nucleotides, wherein the nucleotide sequence comprises a seed region consisting of nucleotide positions 1 to 12, wherein position 1 represents the 5′ end of the iRNA nucleotide sequence and wherein said seed region comprises a nucleotide sequence of at least six contiguous nucleotides that is complementary to six contiguous nucleotides within positions 1 to 12 of a nucleotide sequence, wherein position 1 represents the 5″end of the nucleotide sequence, wherein the nucleotide sequence is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7 and SEQ ID NO:8. In some embodiments, the method comprises introducing at least one iRNA that inhibits the expression of at least one miR-16 responsive gene selected from TABLE 5 into the mammalian cell.

First claim

The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows:

1. A method of inhibiting proliferation of a mammalian cell comprising:
introducing into said cell an effective amount of small interfering RNA agents (iRNAs) that inhibit the expression of the miR-16 responsive genes represented by target sequences SEQ ID NOS:366, 368, 370, and 372;
wherein each of the miR-16 responsive genes comprises a nucleotide sequence of at least six contiguous nucleotides that is complementary to at least six contiguous nucleotides located within positions 1 to 12 of SEQ ID NO:3; and
wherein each of the iRNAs is at least 15 nucleotides in length and comprises a gene specific a nucleotide sequence that is substantially identical to the complement of a portion of an mRNA encoded by a target miR-16 responsive gene as represented by a gene target sequence selected from SEQ ID NOS:366, 368, 370, and 372.

2. The method of claim 1 , wherein the at least six contiguous nucleotides located within positions 1 to 12 of SEQ ID NO:3 are identical to at least six contiguous nucleotides located within positions 1 to 12 of SEQ ID NO:1.

3. The method of claim 1 , wherein the at least six contiguous nucleotides located within positions 1 to 12 of SEQ ID NO:3 are identical to at least six contiguous nucleotides located within positions 1 to 12 of SEQ ID NO:2.

4. The method of claim 1 , wherein the at least six contiguous nucleotides located within positions 1 to 12 of SEQ ID NO:3 are identical to at least six contiguous nucleotides located within positions 1 to 12 of SEQ ID NO:4.

5. The method of claim 1 , wherein the at least six contiguous nucleotides located within positions 1 to 12 of SEQ ID NO:3 are identical to at least six contiguous nucleotides located within positions 1 to 12 of SEQ ID NO:5.

6. The method of claim 1 , wherein the at least six contiguous nucleotides located within positions 1 to 12 of SEQ ID NO:3 are identical to at least six contiguous nucleotides located within positions 1 to 12 of SEQ ID NO:6.

7. The method of claim 1 , wherein the at least six contiguous nucleotides located within positions 1 to 12 of SEQ ID NO:3 are identical to at least six contiguous nucleotides located within positions 1 to 12 of SEQ ID NO:7.

8. The method of claim 1 , wherein the target miR-16 responsive gene comprises a nucleotide sequence that is complementary to eight contiguous nucleotides located within SEQ ID NO:3.

9. The method of claim 1 , wherein the mammalian cell is a cancer cell.

10. The method of claim 1 , wherein the mammalian cell is infected with a virus expressing a micro RNA species in the miR-16 family.

11. The method of claim 10 , wherein the mammalian cell is infected with kshv-miR-K12-6-5p.

12. The method of claim 1 , wherein at least one of the iRNA agents comprises at least one chemically modified nucleotide or non-nucleotide.

13. The method of claim 1 , wherein at least one of the iRNA agents comprises a dsRNA molecule comprising one nucleotide strand that is substantially identical to a portion of the mRNA encoded by at least one of the genes represented by a target sequence selected from SEQ ID NOS:366, 368, 370, and 372.

14. The method of claim 1 , wherein at least one of the iRNA agents comprises a ssRNA molecule comprising one nucleotide strand that is substantially complementary to a portion of the mRNA encoded by at least one of the genes represented by a target sequence selected from SEQ ID NOS:366, 368, 370, and 372.

15. The method of claim 1 , wherein at least one of the iRNA agents is at least one dsRNA molecule comprising a double-stranded region, wherein one strand of the double-stranded region is substantially identical to 15 to 25 consecutive nucleotides encoded by a gene represented by a target sequence selected from SEQ ID NOS:366, 368, 370, and 372 and the second strand is substantially complementary to the first, and wherein at least one end of the dsRNA has an overhang of 1 to 4 nucleotides.

16. The method of claim 1 , wherein at least one of the iRNA agents comprises at least one dsRNA molecule comprising at least one of SEQ ID NO:272-277, SEQ NO:284-289, SEQ ID NO:290-295, SEQ ID NO:248-253, SEQ ID NO:344-349, SEQ ID NO:350-355, SEQ ID NO:356-361.

17. The method of claim 9 , wherein the cancer cell is an miR-16 mediated cancer cell.

18. The method of claim 1 , wherein at least one of the miR-16 responsive genes further comprises a nucleotide sequence of at least six contiguous nucleotides that is complementary to at least six contiguous nucleotides located within positions 1 to 12 of SEQ ID NO: 1, wherein position 1 represents the 5′ end of SEQ ID NO: 1.

19. The method of claim 1 , wherein at least one of the miR-16 responsive genes further comprises a nucleotide sequence of at least six contiguous nucleotides that is complementary to at least six contiguous nucleotides located within positions 1 to 12 of SEQ ID NO: 2, wherein position 1 represents the 5′ end of SEQ ID NO:2.

20. The method of claim 1 , wherein at least one of the miR-16 responsive genes further comprises a nucleotide sequence of at least six contiguous nucleotides that is complementary to at least six contiguous nucleotides located within positions 1 to 12 of SEQ ID NO:4, wherein position 1 represents the 5′ end of SEQ ID NO:4.

21. The method of claim 1 , wherein at least one of the miR-16 responsive genes further comprises a nucleotide sequence of at least six contiguous nucleotides that is complementary to at least six contiguous nucleotides located within positions 1 to 12 of SEQ ID NO:5, wherein position 1 represents the 5′ end of SEQ ID NO:5.

22. The method of claim 1 , wherein at least one of the miR-16 responsive genes further comprises a nucleotide sequence of at least six contiguous nucleotides that is complementary to at least six contiguous nucleotides located within positions 1 to 12 of SEQ ID NO:6, wherein position 1 represents the 5′ end of SEQ ID NO:6.

23. The method of claim 1 , wherein at least one of the miR-16 responsive genes further comprises a nucleotide sequence of at least six contiguous nucleotides that is complementary to at least six contiguous nucleotides located within positions 1 to 12 of SEQ ID NO:7, wherein position 1 represents the 5′ end of SEQ ID NO:7.

Assignees

• Linsley Peter S
• Schelter Janell
• Burchard Julja
• Lim Lee
• Kibukawa Miho
• Merck Sharp & Dohme

Inventors

• Linsley Peter S
• Schelter Janell
• Burchard Julja
• Lim Lee
• Kibukawa Miho

Classifications

• C12N2330/10

  naturally occurring · CPC title

• C12N2330/31

  Libraries, arrays · CPC title

• C12N2320/12

  in functional genomics, i.e. for the determination of gene function · CPC title

• C12N2310/14

  interfering nucleic acids [NA] · CPC title

• C12N15/111 Primary

  General methods applicable to biologically active non-coding nucleic acids · CPC title